From 11:00 pm to 12:00 pm EST ( 8:00 pm to 9:00 pm PST ) on January 6th, the website will be under maintenance. We are sorry for the inconvenience. Please arrange your schedule properly.
Epacadostat (INCB 024360) is a potent and selective indoleamine 2,3-dioxigenase 1 (IDO1) inhibitor with an IC50 of 71.8 nM . Epacadostat can effectively reduce Trp metabolism, entailing increased activation and maturation of dendritic cells, and enhanced proliferation of effector T cells and naturalkiller cells (NKs), as well as attenuated Tregs expansion.
Amivantamab (JNJ-61186372) is a human EGFR-MET bispecific antibody with immune anticancer activity. Amivantamab inhibits ligand binding, promotes endocytosis and degradation of receptor-antibody complexes, and induces Fc-dependent cytokinesis in macrophages and antibody-dependent cytotoxicity in naturalkiller cells .
Urelumab, a fully human, non-ligand binding, CD137 agonist IgG4 monoclonal antibody, enhances T-cell and naturalkiller-cell antitumor activity, and may enhance cytotoxic activity of Rituximab (HY-P9913). Urelumab can be used for the research of diffuse large B-cell lymphoma (DLBCL), follicular lymphoma (FL), and other types of non-Hodgkin lymphoma (NHL) .
trans-urocanic acid (trans-UCA), a natural epidermal constituent, inhibits human naturalkiller cell (NK) activity in vitro. trans-urocanic acid is active in regulating an immune function .
Elotuzumab (HuLuc 63) is an IgG1 monoclonal antibody targeting the SLAMF7 receptor. Elotuzumab exerts antitumor activity by activating naturalkiller cells and inducing antibody-dependent cell-mediated cytotoxicity. Elotuzumab can be combined with Lenalidomide (HY-A0003), Dexamethasone (HY-14648), etc., for the research of tumors such as multiple myeloma .
TREM2-IN-1 (OPA) is a TREM2 inhibitor derived from oxaliplatin and artesunate. TREM2-IN-1 can relieves immunosuppressive tumor microenvironment and enhancing chemical anticancer efficiency. TREM2-IN-1 deters the tumor growth in mice models bearing MC38 colorectal tumor by reducing the number of CD206 + and CX3CR1 + immunosuppressive macrophages. TREM2-IN-1 also promotes the expansion and infiltration of immunostimulatory dendritic, cytotoxic T and naturalkiller cells .
Flavone is an anti-tumor compound that targets cell cycle regulatory proteins (such as cyclin B1) and apoptosis-related factors (such as p21waf1, PIG3). Flavone selectively induces mitochondrial-mediated apoptosis pathways in tumor cells, inhibits cyclin B1 protein expression, upregulates p21waf1, and activates p63/p73 proteins. Flavone has immunomodulatory functions that enhance naturalkiller cell (NK cell) activity and lymphocyte proliferation. Flavone is used in cancer research, especially for its inhibitory potential in solid tumor models such as esophageal cancer and liver cancer .
Tosposertib (TU2218 free base) is an ALK5/VEGFR2 dual inhibitor (IC50 = 1.2 nM/4.9 nM). Tosposertib directly restores the activity of damaged cytotoxic T lymphocytes (CTLs) and naturalkiller cells inhibited by TGFβ and suppresses the activity and viability of regulatory T cells. Tosposertib can be used for the study of melanoma and colon cancer .
S1PR5-IN-1 (Compound 7a) is a highly selective S1PR5 antagonist and orally bioavailable inhibitor with a human S1PR5IC50 of 85.4 nM and human S1PR5Ka of 2.173 nM.S1PR5-IN-1 binds to S1PR5 and inhibits naturalkiller cell migration toward sphingosine-1-phosphate.S1PR5-IN-1 can be used for the research of multiple sclerosis .
Amivantamab (FUT8-KO) is an anti-EGFR-MET monoclonal antibody expressed by CHO cells with the fucosyltransferase 8 gene (FUT8) knocked out. Fucose deficiency enhances the ADCC effect of the antibody. Amivantamab (FUT8-KO) inhibits ligand binding, promotes endocytosis and degradation of receptor-antibody complexes, and induces Fc-dependent cytokinesis in macrophages and antibody-dependent cytotoxicity in naturalkiller cells .
HEI3090 is a P2X7R activator. HEI3090 stimulates dendritic cells expressing P2X7R to produce IL-18, which subsequently promotes NaturalKiller cells and CD4 T cells within tumors to produce IFN-γ, leading to a sustained antitumor response. HEI3090 can be used to enhance the efficacy of αPD-1 therapy in non-small cell lung cancer (NSCLC) .
Anti-Mouse NKG2D/CD314 Antibody (CX5) is a rat-derived IgG1 κ type antibody inhibitor, targeting to mouse NKG2D/CD314. Anti-Mouse NKG2D/CD314 Antibody (CX5) reduces cytotoxicity of naturalkiller cells. Anti-Mouse NKG2D/CD314 Antibody (CX5) can be used for the researches of cancer, infection, inflammation, immunology and metabolic disease, such as colitis and diabetes .
Human CD70 mRNA encodes the human CD70 molecule (CD70) protein, a cytokine that belongs to the tumor necrosis factor (TNF) ligand family. CD70 induces proliferation of costimulated T cells, enhances the generation of cytolytic T cells, and contributes to T cell activation. It is also reported to play a role in regulating B-cell activation, cytotoxic function of naturalkiller cells, and immunoglobulin sythesis.
SCL-1 is an orally active anti-PD-1/PD-L1 inhibitor. SCL-1 can inhibit PD-1/PD-L1 binding. SCL-1 increases T cells, B cells and naturalkiller cells. SCL-1 exerts strong tumor growth inhibitory effects that were mediated by effector T-cell induction inside tumors and the up-regulated expression of long non-coding RNAs as neoantigens leading to cytotoxic T lymphocyte activation. SCL-1 can be used for the research of cancer, such as triple-negative breast cancer .
Bexatamig (SAR-443579) is a trifunctional naturalkiller cell engager targeting IL-3R α/CD123, NKp46/NCR1/CD335 and Fc gamma RIIIA/CD16a. Bexatamig forms a cytolytic synapse between naturalkiller cells and CD123-positive tumor cells. By activating naturalkiller cells to induce tumor cell death, Bexatamig effectively reduces the burden of CD123-positive acute myeloid leukemia (AML) blasts. Bexatamig has been granted FDA Fast Track designation, and is primarily investigated for relapsed or refractory acute myeloid leukemia, B-cell acute lymphoblastic leukemia, and high-risk myelodysplastic syndromes .
Human IL12A mRNA encodes the human interleukin 12A (IL12A) protein, a subunit of a cytokine that acts on T and naturalkiller cells, and has a broad array of biological activities. IL12A is required for the T-cell-independent induction of interferon (IFN)-gamma, and is important for the differentiation of both Th1 and Th2 cells.
Human IL12B mRNA encodes the human interleukin 12B (IL12B) protein, a subunit of interleukin 12, is a cytokine that acts on T and naturalkiller cells, and has a broad array of biological activities. IL12B has been found to be important for sustaining a sufficient number of memory/effector Th1 cells to mediate long-term protection to an intracellular pathogen.
trans-Urocanic acid (Standard) is the analytical standard of trans-Urocanic acid. This product is intended for research and analytical applications. trans-urocanic acid (trans-UCA), a natural epidermal constituent, inhibits human naturalkiller cell (NK) activity in vitro. trans-urocanic acid is active in regulating an immune function .
Human IL15 mRNA encodes the human interleukin 15 (IL15) protein, a cytokine that regulates T and naturalkiller cell activation and proliferation. IL15 induces the activation of JAK kinases, as well as the phosphorylation and activation of transcription activators STAT3, STAT5, and STAT6.
Human IL33 mRNA encodes the human interleukin 33 (IL33) protein, a cytokine that binds to the IL1RL1/ST2 receptor. IL33 is involved in the maturation of Th2 cells and the activation of mast cells, basophils, eosinophils and naturalkiller cells.
Human IL21 mRNA encodes the human interleukin 21 (IL21) protein, a member of the common-gamma chain family of cytokines. IL21 plays a role in both the innate and adaptive immune responses by inducing the differentiation, proliferation and activity of multiple target cells including macrophages, naturalkiller cells, B cells and cytotoxic T cells.
Human CCL22 mRNA encodes the human C-C motif chemokine ligand 22 (CCL22) protein, a cytokine that displays chemotactic activity for monocytes, dendritic cells, naturalkiller cells and for chronically activated T lymphocytes. CCL22 also displays a mild activity for primary activated T lymphocytes and has no chemoattractant activity for neutrophils, eosinophils and resting T lymphocytes.
MSH-TP15e is a humanized monoclonal antibody inhibitor targeting intercellular adhesion molecule-1 (ICAM-1). MSH-TP15e recruits naturalkiller cells and significantly triggers antibody-dependent cell-mediated cytotoxicity (ADCC) to inhibit tumor cell growth. MSH-TP15e is promising for research of multiple myeloma (MM) .
EBNA3B 399-408 is an immunodominant HLA-A11-restricted cytotoxic T-lymphocyte epitope in EBNA3B. EBNA3B 399-408 can be used in the research of EBV infection, empyema-associated lymphoma, and nasal naturalkiller cell lymphoma .
OX118 is a fully human, ADCC-enhanced monoclonal antibody targeting OX40L, the recommended isotype control is HY-P99001. OX118 blocks OX40L, suppresses effector T-cell proliferation, expands regulatory T-cell populations, and reduces bystander activation across naturalkiller cells, B cells, and CD14+ monocytes. OX118 can be used for the research of graft-versus-host disease .
S1P5 receptor antagonist 1 is a selective, blood-brain barrier-permeable S1P5 receptor antagonist with an EC50 of 0.1 nM and a Ki of 4.4 nM. S1P5 receptor antagonist 1 inhibits the migration of naturalkiller cells towards sphingosine 1-phosphate in vitro, with no effect on T cell migration. S1P5 receptor antagonist 1 can be used in the research of central nervous system diseases .
TLR8 agonist 10 is a selective TLR8 agonist with an EC50 of 0.019 μM in humans. TLR8 agonist 10 activates TLR8-mediated signaling pathways. As a latency-reversing agent, TLR8 agonist 10 reactivates latent HIV-1 reservoirs. TLR8 agonist 10 activates innate cytotoxic naturalkiller cells to target HIV-infected CD4 + T cells. TLR8 agonist 10 is applicable to research related to HIV-1 infection .
SHP1‑IN‑2 is a selective and orally active SHP1 inhibitor. SHP1‑IN‑2 covalently binds to Cys480 of SHP1. SHP1‑IN‑2 elicits potent antitumor immunity and suppresses syngeneic tumor growth. SHP1‑IN‑2 blocks tumor progression in a svngeneic cancer model by
activating naturalkiller cells and cytotoxic CD8 ＋ T cells, along with reduced T cel
l. SHP1‑IN‑2 can be used for cancer‑related research .
YH004 is an anti-CD137 agonistic monoclonal antibody, with immunostimulating and antineoplastic activities. YH004 activates CD137 expressed on a variety of leukocyte subsets including activated T lymphocytes and naturalkiller cells. YH004 enhances CD137-mediated signaling and induces cytotoxic T-lymphocyte (CTL) proliferation, cytokine production and promotes anti-tumor response mediated by CTL. YH004 induces NK-mediated tumor cell killing and suppresses the immunosuppressive activity of regulatory T cells. YH004 can be studied in anticancer research .
IT9302 is a synthetic IL-10 agonist with the activity of inducing tolerogenic dendritic cells. IT9302 is able to mimic multiple effects of IL-10, including downregulating the antigen presentation machinery and increasing the sensitivity of tumor cells to naturalkiller cell-mediated lysis. IT9302 can also hinder the response of human monocytes to differentiation factors and reduce the antigen presentation and co-stimulatory capacity of dendritic cells. Dendritic cells treated with IT9302 showed a weakened ability to stimulate T cell proliferation and interferon-γ production. IT9302 exerts its effects through mechanisms that are partially different from IL-10, involving STAT3 inactivation and regulation of the NF-κB intracellular pathway. IT9302-treated dendritic cells showed enhanced expression of membrane-bound TGF-β, associated with the effective induction of foxp3+ regulatory T cells .
EBNA3B 399-408 is an immunodominant HLA-A11-restricted cytotoxic T-lymphocyte epitope in EBNA3B. EBNA3B 399-408 can be used in the research of EBV infection, empyema-associated lymphoma, and nasal naturalkiller cell lymphoma .
Amivantamab (JNJ-61186372) is a human EGFR-MET bispecific antibody with immune anticancer activity. Amivantamab inhibits ligand binding, promotes endocytosis and degradation of receptor-antibody complexes, and induces Fc-dependent cytokinesis in macrophages and antibody-dependent cytotoxicity in naturalkiller cells .
Urelumab, a fully human, non-ligand binding, CD137 agonist IgG4 monoclonal antibody, enhances T-cell and naturalkiller-cell antitumor activity, and may enhance cytotoxic activity of Rituximab (HY-P9913). Urelumab can be used for the research of diffuse large B-cell lymphoma (DLBCL), follicular lymphoma (FL), and other types of non-Hodgkin lymphoma (NHL) .
Elotuzumab (HuLuc 63) is an IgG1 monoclonal antibody targeting the SLAMF7 receptor. Elotuzumab exerts antitumor activity by activating naturalkiller cells and inducing antibody-dependent cell-mediated cytotoxicity. Elotuzumab can be combined with Lenalidomide (HY-A0003), Dexamethasone (HY-14648), etc., for the research of tumors such as multiple myeloma .
Amivantamab (FUT8-KO) is an anti-EGFR-MET monoclonal antibody expressed by CHO cells with the fucosyltransferase 8 gene (FUT8) knocked out. Fucose deficiency enhances the ADCC effect of the antibody. Amivantamab (FUT8-KO) inhibits ligand binding, promotes endocytosis and degradation of receptor-antibody complexes, and induces Fc-dependent cytokinesis in macrophages and antibody-dependent cytotoxicity in naturalkiller cells .
Anti-Mouse NKG2D/CD314 Antibody (CX5) is a rat-derived IgG1 κ type antibody inhibitor, targeting to mouse NKG2D/CD314. Anti-Mouse NKG2D/CD314 Antibody (CX5) reduces cytotoxicity of naturalkiller cells. Anti-Mouse NKG2D/CD314 Antibody (CX5) can be used for the researches of cancer, infection, inflammation, immunology and metabolic disease, such as colitis and diabetes .
Etuptamig is a chimeric monoclonal antibody of immunoglobulin λ-chain-γ1, λ-chain-γ3 targeting human naturalkiller cell cytotoxicity receptor 1 (NCR1). Etuptamig is promising for research of various cancers .
Bexatamig (SAR-443579) is a trifunctional naturalkiller cell engager targeting IL-3R α/CD123, NKp46/NCR1/CD335 and Fc gamma RIIIA/CD16a. Bexatamig forms a cytolytic synapse between naturalkiller cells and CD123-positive tumor cells. By activating naturalkiller cells to induce tumor cell death, Bexatamig effectively reduces the burden of CD123-positive acute myeloid leukemia (AML) blasts. Bexatamig has been granted FDA Fast Track designation, and is primarily investigated for relapsed or refractory acute myeloid leukemia, B-cell acute lymphoblastic leukemia, and high-risk myelodysplastic syndromes .
MSH-TP15e is a humanized monoclonal antibody inhibitor targeting intercellular adhesion molecule-1 (ICAM-1). MSH-TP15e recruits naturalkiller cells and significantly triggers antibody-dependent cell-mediated cytotoxicity (ADCC) to inhibit tumor cell growth. MSH-TP15e is promising for research of multiple myeloma (MM) .
OX118 is a fully human, ADCC-enhanced monoclonal antibody targeting OX40L, the recommended isotype control is HY-P99001. OX118 blocks OX40L, suppresses effector T-cell proliferation, expands regulatory T-cell populations, and reduces bystander activation across naturalkiller cells, B cells, and CD14+ monocytes. OX118 can be used for the research of graft-versus-host disease .
YH004 is an anti-CD137 agonistic monoclonal antibody, with immunostimulating and antineoplastic activities. YH004 activates CD137 expressed on a variety of leukocyte subsets including activated T lymphocytes and naturalkiller cells. YH004 enhances CD137-mediated signaling and induces cytotoxic T-lymphocyte (CTL) proliferation, cytokine production and promotes anti-tumor response mediated by CTL. YH004 induces NK-mediated tumor cell killing and suppresses the immunosuppressive activity of regulatory T cells. YH004 can be studied in anticancer research .
trans-urocanic acid (trans-UCA), a natural epidermal constituent, inhibits human naturalkiller cell (NK) activity in vitro. trans-urocanic acid is active in regulating an immune function .
Flavone is an anti-tumor compound that targets cell cycle regulatory proteins (such as cyclin B1) and apoptosis-related factors (such as p21waf1, PIG3). Flavone selectively induces mitochondrial-mediated apoptosis pathways in tumor cells, inhibits cyclin B1 protein expression, upregulates p21waf1, and activates p63/p73 proteins. Flavone has immunomodulatory functions that enhance naturalkiller cell (NK cell) activity and lymphocyte proliferation. Flavone is used in cancer research, especially for its inhibitory potential in solid tumor models such as esophageal cancer and liver cancer .
trans-Urocanic acid (Standard) is the analytical standard of trans-Urocanic acid. This product is intended for research and analytical applications. trans-urocanic acid (trans-UCA), a natural epidermal constituent, inhibits human naturalkiller cell (NK) activity in vitro. trans-urocanic acid is active in regulating an immune function .
CD160 Protein, Human (HEK293, Fc) is a recombinant human CD160 expressed in HEK 293 cells with a C-Fc tag at the C-terminus. CD160 Protein binds weakly to MHC I and stimulates NK and CD8+ T‐cell activation.
KIR3DS1/CD158e2, located on NK cells, serves as a receptor for MHC class I molecules. Its crucial role includes triggering NK cell degranulation and inducing the production of anti-viral cytokines upon interaction with the peptide-free HLA-F open conformer. This direct engagement highlights KIR3DS1/CD158e2 as a key modulator of NK cell responses, particularly in anti-viral immune reactions. KIR3DS1/CD158e2 Protein, Human (CHO, His) is the recombinant human-derived KIR3DS1/CD158e2 protein, expressed by CHO , with tag free.
2B4/CD244 protein exhibits heightened affinity for binding to CD48, surpassing isoform 1, leading to increased cytotoxicity and intracellular calcium release. The stronger interaction implies more robust engagement, potentially amplifying cellular responses, particularly heightened cytotoxic activity and intracellular calcium release. 2B4/CD244 Protein, Human (HEK293, His) is the recombinant human-derived 2B4/CD244 protein, expressed by HEK293 , with C-6*His labeled tag.
The CD244 protein is an activating receptor that regulates NK cells and CD8+ T cells. It enhances NK cell cytotoxicity, IFN-γ production, and granule exocytosis. 2B4/CD244 Protein, Mouse (HEK293, His) is the recombinant mouse-derived 2B4/CD244 protein, expressed by HEK293 , with C-6*His labeled tag.
KIR2DL3, found on NK cells, selectively recognizes HLA-C alleles like HLA-Cw1, HLA-Cw3, and HLA-Cw7. Its interaction leads to inhibitory effects, preventing NK cell activity and cell lysis. KIR2DL3's association with ARRB2 underscores its role in cellular signaling pathways, intricately modulating NK cell functions. KIR2DL3 Protein, Human (HEK293, His) is the recombinant human-derived KIR2DL3 protein, expressed by HEK293 , with C-6*His labeled tag.
Peroxiredoxin-1 (PRDX1) is a thiol-specific peroxidase that catalyzes the reduction of hydrogen peroxide and organic hydroperoxides and plays a crucial role in cellular protection against oxidative stress. It detoxifies peroxide and senses hydrogen peroxide-mediated signaling events. PRDX1/Peroxiredoxin-1 Protein, Human (His) is the recombinant human-derived PRDX1 protein, expressed by E. coli , with C-6*His, N-6*His labeled tag.
KIR2DS3, present on NK cells, selectively recognizes HLA-C alleles. In contrast to inhibitory KIRs, KIR2DS3 lacks inhibitory effects on NK cell activity. Its role is likely in activating or modulating NK cell functions, contributing to the nuanced balance of signals regulating the immune response. KIR2DS3 Protein, Human (P.pastoris, His) is the recombinant human-derived KIR2DS3 protein, expressed by P. pastoris , with N-His labeled tag.
Peroxiredoxin-2 (PRDX2) is a thiol-specific peroxidase that catalyzes the reduction of hydrogen peroxide and organic hydroperoxides, which is essential for cellular protection against oxidative stress. It detoxifies peroxide, senses hydrogen peroxide-mediated signaling events, and may participate in signaling cascades initiated by growth factors and tumor necrosis factor-alpha. Peroxiredoxin-2/PRDX2 Protein, Human (His) is the recombinant human-derived Peroxiredoxin-2/PRDX2 protein, expressed by E. coli , with N-His labeled tag.
NKp46/NCR1 Protein is a major NK cell-activating receptor that is involved in the elimination of target cells and recognizing a wide range of tumors, viruses, and bacteria. NKp46 forms microclusters structures at the immune synapse between NK cells and target cells. Over-expression of human NKp46 is correlated with increased accumulation of F-actin mesh at the immune synapse. NKp46 signaling directly regulates the NK lytic immune synapse from early formation to late function. NKp46/NCR1 Protein, Human (HEK293, Fc) is the recombinant human-derived NKp46/NCR1 protein, expressed by HEK293 , with C-hFc labeled tag.
NKp46/NCR1 protein, a cytotoxicity-activating receptor on natural killer (NK) cells, potentially enhances their efficacy in tumor cell lysis. Interacting with CD247 and FCER1G, NKp46/NCR1 plays a pivotal role in signaling pathways associated with NK cell activation and cytotoxicity. It contributes to the regulatory network for recognizing and eliminating target cells, emphasizing its importance in immune surveillance and anti-tumor responses. NKp46/NCR1 Protein, Human (HEK293, Llama Fc) is the recombinant human-derived NKp46/NCR1 protein, expressed by HEK293, with C-Llama Fc labeled tag.
KLRB1; CLEC5B; NKRP1A; killercell lectin-like receptor subfamily B member 1; C-type lectin domain family 5 member B; HNKR-P1a; NKR-P1A; naturalkillercell surface protein P1A; CD161
CD161 Antibody (YA4661) is a non-conjugated antibody, targeting to CD161.
Human CD70 mRNA encodes the human CD70 molecule (CD70) protein, a cytokine that belongs to the tumor necrosis factor (TNF) ligand family. CD70 induces proliferation of costimulated T cells, enhances the generation of cytolytic T cells, and contributes to T cell activation. It is also reported to play a role in regulating B-cell activation, cytotoxic function of naturalkiller cells, and immunoglobulin sythesis.
Human IL12A mRNA encodes the human interleukin 12A (IL12A) protein, a subunit of a cytokine that acts on T and naturalkiller cells, and has a broad array of biological activities. IL12A is required for the T-cell-independent induction of interferon (IFN)-gamma, and is important for the differentiation of both Th1 and Th2 cells.
Human IL12B mRNA encodes the human interleukin 12B (IL12B) protein, a subunit of interleukin 12, is a cytokine that acts on T and naturalkiller cells, and has a broad array of biological activities. IL12B has been found to be important for sustaining a sufficient number of memory/effector Th1 cells to mediate long-term protection to an intracellular pathogen.
Human IL15 mRNA encodes the human interleukin 15 (IL15) protein, a cytokine that regulates T and naturalkiller cell activation and proliferation. IL15 induces the activation of JAK kinases, as well as the phosphorylation and activation of transcription activators STAT3, STAT5, and STAT6.
Human IL33 mRNA encodes the human interleukin 33 (IL33) protein, a cytokine that binds to the IL1RL1/ST2 receptor. IL33 is involved in the maturation of Th2 cells and the activation of mast cells, basophils, eosinophils and naturalkiller cells.
Human IL21 mRNA encodes the human interleukin 21 (IL21) protein, a member of the common-gamma chain family of cytokines. IL21 plays a role in both the innate and adaptive immune responses by inducing the differentiation, proliferation and activity of multiple target cells including macrophages, naturalkiller cells, B cells and cytotoxic T cells.
Human CCL22 mRNA encodes the human C-C motif chemokine ligand 22 (CCL22) protein, a cytokine that displays chemotactic activity for monocytes, dendritic cells, naturalkiller cells and for chronically activated T lymphocytes. CCL22 also displays a mild activity for primary activated T lymphocytes and has no chemoattractant activity for neutrophils, eosinophils and resting T lymphocytes.
Inquiry Online
Your information is safe with us. * Required Fields.
Western blot analysis of extracts from THP-1(lane 2(20μg), Jurkat (lane 3(20μg) and NIH3T3(lane 4(20μg) using FOXO1A (HY-P80132) Rabbit mAb. Proteins were transferred
to a PVDF membrane and blocked with 5% non-fat milk in TBST for 2 hour at room temperature. The primary antibody (1/1000) and Loading control antibody (Beta Actin, HY-P80438, 1/10000) was
used in 5% non-fat milk in TBST at 4°C overnight. Goat Anti-Mouse/Rabbit IgG-HRP Secondary Antibody (1/10000) was used for 1 hour at room temperature.
Western blot analysis of extracts from THP-1(lane 2(20μg), Jurkat (lane 3(20μg) and NIH3T3(lane 4(20μg) using FOXO1A (HY-P80132) Rabbit mAb. Proteins were transferred
to a PVDF membrane and blocked with 5% non-fat milk in TBST for 2 hour at room temperature. The primary antibody (1/1000) and Loading control antibody (Beta Actin, HY-P80438, 1/10000) was
used in 5% non-fat milk in TBST at 4°C overnight. Goat Anti-Mouse/Rabbit IgG-HRP Secondary Antibody (1/10000) was used for 1 hour at room temperature.
Western blot analysis of extracts from THP-1(lane 2(20μg), Jurkat (lane 3(20μg) and NIH3T3(lane 4(20μg) using FOXO1A (HY-P80132) Rabbit mAb. Proteins were transferred
to a PVDF membrane and blocked with 5% non-fat milk in TBST for 2 hour at room temperature. The primary antibody (1/1000) and Loading control antibody (Beta Actin, HY-P80438, 1/10000) was
used in 5% non-fat milk in TBST at 4°C overnight. Goat Anti-Mouse/Rabbit IgG-HRP Secondary Antibody (1/10000) was used for 1 hour at room temperature.
Western blot analysis of extracts from THP-1(lane 2(20μg), Jurkat (lane 3(20μg) and NIH3T3(lane 4(20μg) using FOXO1A (HY-P80132) Rabbit mAb. Proteins were transferred
to a PVDF membrane and blocked with 5% non-fat milk in TBST for 2 hour at room temperature. The primary antibody (1/1000) and Loading control antibody (Beta Actin, HY-P80438, 1/10000) was
MedchemExpress Validation 03
Western blot analysis of extracts from THP-1(lane 2(20μg), Jurkat (lane 3(20μg) and NIH3T3(lane 4(20μg) using FOXO1A (HY-P80132) Rabbit mAb. Proteins were transferred
MedchemExpress Validation 04
Western blot analysis of extracts from THP-1(lane 2(20μg), Jurkat (lane 3(20μg) and NIH3T3(lane 4(20μg) using FOXO1A (HY-P80132) Rabbit mAb. Proteins were transferred
to a PVDF membrane and blocked with 5% non-fat milk in TBST for 2 hour at room temperature. The primary antibody (1/1000) and Loading control antibody (Beta Actin, HY-P80438, 1/10000) was
used in 5% non-fat milk in TBST at 4°C overnight. Goat Anti-Mouse/Rabbit IgG-HRP Secondary Antibody (1/10000) was used for 1 hour at room temperature.
MedchemExpress Validation
Western blot analysis of extracts from THP-1(lane 2(20μg), Jurkat (lane 3(20μg) and NIH3T3(lane 4(20μg) using FOXO1A (HY-P80132) Rabbit mAb. Proteins were transferred
to a PVDF membrane and blocked with 5% non-fat milk in TBST for 2 hour at room temperature. The primary antibody (1/1000) and Loading control antibody (Beta Actin, HY-P80438, 1/10000) was
used in 5% non-fat milk in TBST at 4°C overnight. Goat Anti-Mouse/Rabbit IgG-HRP Secondary Antibody (1/10000) was used for 1 hour at room temperature.
Western blot analysis of extracts from THP-1(lane 2(20μg), Jurkat (lane 3(20μg) and NIH3T3(lane 4(20μg) using FOXO1A (HY-P80132) Rabbit mAb. Proteins were transferred
to a PVDF membrane and blocked with 5% non-fat milk in TBST for 2 hour at room temperature. The primary antibody (1/1000) and Loading control antibody (Beta Actin, HY-P80438, 1/10000) was
used in 5% non-fat milk in TBST at 4°C overnight. Goat Anti-Mouse/Rabbit IgG-HRP Secondary Antibody (1/10000) was used for 1 hour at room temperature.
MedchemExpress Validation
Western blot analysis of extracts from THP-1(lane 2(20μg), Jurkat (lane 3(20μg) and NIH3T3(lane 4(20μg) using FOXO1A (HY-P80132) Rabbit mAb. Proteins were transferred
to a PVDF membrane and blocked with 5% non-fat milk in TBST for 2 hour at room temperature. The primary antibody (1/1000) and Loading control antibody (Beta Actin, HY-P80438, 1/10000) was
used in 5% non-fat milk in TBST at 4°C overnight. Goat Anti-Mouse/Rabbit IgG-HRP Secondary Antibody (1/10000) was used for 1 hour at room temperature.
MedchemExpress Validation
Western blot analysis of extracts from THP-1(lane 2(20μg), Jurkat (lane 3(20μg) and NIH3T3(lane 4(20μg) using FOXO1A (HY-P80132) Rabbit mAb. Proteins were transferred
to a PVDF membrane and blocked with 5% non-fat milk in TBST for 2 hour at room temperature. The primary antibody (1/1000) and Loading control antibody (Beta Actin, HY-P80438, 1/10000) was
used in 5% non-fat milk in TBST at 4°C overnight. Goat Anti-Mouse/Rabbit IgG-HRP Secondary Antibody (1/10000) was used for 1 hour at room temperature.
MedchemExpress Validation
Western blot analysis of extracts from THP-1(lane 2(20μg), Jurkat (lane 3(20μg) and NIH3T3(lane 4(20μg) using FOXO1A (HY-P80132) Rabbit mAb. Proteins were transferred
to a PVDF membrane and blocked with 5% non-fat milk in TBST for 2 hour at room temperature. The primary antibody (1/1000) and Loading control antibody (Beta Actin, HY-P80438, 1/10000) was
used in 5% non-fat milk in TBST at 4°C overnight. Goat Anti-Mouse/Rabbit IgG-HRP Secondary Antibody (1/10000) was used for 1 hour at room temperature.
MedchemExpress Validation
Western blot analysis of extracts from THP-1(lane 2(20μg), Jurkat (lane 3(20μg) and NIH3T3(lane 4(20μg) using FOXO1A (HY-P80132) Rabbit mAb. Proteins were transferred
to a PVDF membrane and blocked with 5% non-fat milk in TBST for 2 hour at room temperature. The primary antibody (1/1000) and Loading control antibody (Beta Actin, HY-P80438, 1/10000) was
used in 5% non-fat milk in TBST at 4°C overnight. Goat Anti-Mouse/Rabbit IgG-HRP Secondary Antibody (1/10000) was used for 1 hour at room temperature.
MedchemExpress Validation
Western blot analysis of extracts from THP-1(lane 2(20μg), Jurkat (lane 3(20μg) and NIH3T3(lane 4(20μg) using FOXO1A (HY-P80132) Rabbit mAb. Proteins were transferred
to a PVDF membrane and blocked with 5% non-fat milk in TBST for 2 hour at room temperature. The primary antibody (1/1000) and Loading control antibody (Beta Actin, HY-P80438, 1/10000) was
used in 5% non-fat milk in TBST at 4°C overnight. Goat Anti-Mouse/Rabbit IgG-HRP Secondary Antibody (1/10000) was used for 1 hour at room temperature.
MedchemExpress Validation
Western blot analysis of extracts from THP-1(lane 2(20μg), Jurkat (lane 3(20μg) and NIH3T3(lane 4(20μg) using FOXO1A (HY-P80132) Rabbit mAb. Proteins were transferred
to a PVDF membrane and blocked with 5% non-fat milk in TBST for 2 hour at room temperature. The primary antibody (1/1000) and Loading control antibody (Beta Actin, HY-P80438, 1/10000) was
used in 5% non-fat milk in TBST at 4°C overnight. Goat Anti-Mouse/Rabbit IgG-HRP Secondary Antibody (1/10000) was used for 1 hour at room temperature.
MedChemExpress values your privacy and your trust is important to us. We use cookies to enhance your website experience. Some cookies are necessary to run the website.
Privacy and Cookie Policy
